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Abstract Allosteric drugs are increasingly used because they produce fewer side effects. 
Allosteric signal propagation does not stop at the ‘end’ of a protein, but may be dynamically 
transmitted across the cell. Here, we propose that the concept of allosteric drugs can be 
broadened to allo-network drugs, whose effects can propagate either within a protein, or across 
several proteins, to enhance or inhibit specific interactions along a pathway. We posit that 
current allosteric drugs are a special case of allo-network drugs, and suggest that allo-network 
drugs can achieve specific, limited changes at the systems level, and in this way can achieve 
fewer side effects and lower toxicity. Finally, we propose steps and methods to identify allo-
network drug targets and sites outlining a new paradigm in systems-based drug design.  
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The chemical view and the network view of the cell are complementary 
Almost a decade ago, Hiroaki Kitano aptly noted “To understand biology at the system level, we 
must examine the structure and dynamics of cellular and organismal function, rather than the 
characteristics of isolated parts of a cell or organism” [1]. Kitano considered four systems 
properties: systems structures, dynamics, control and design. However, a mechanistic 
understanding of each property requires knowledge of the molecular structures, their 
associations, and their conformational dynamics. Together, these could provide an insight into 
why certain mutations can lead to disease, which on their own neither the knowledge of protein 
structures nor of protein-protein interaction networks may be able to achieve. Human perception 
often divides problems between scientific disciplines for convenience; however, such divisions 
do not exist in nature. Proteins, the key workhorse of the cell, are a case in point: the chemical 
view of protein molecules is of conformational ensembles; the network view perceives proteins 
as nodes in cellular networks. Chemists seek drugs against malfunctioning molecules; 
mathematicians and physicists consider the effects of drugs on networks of nodes and edges 
(interactions). Here we argue that the two views can be integrated, and this may expand the 
repertoire of drug targets.  
 
The concepts of allosteric drugs and cellular networks 
On the molecular level, orthosteric sites in related proteins are often similar because active sites 
evolved (or were preserved) to interact with similar ligands; consequently, drugs developed 
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against one protein can often bind another. This is unlikely to be the case for allosteric drugs, 
because they bind on the protein surface away from the active site. Thus they can be more 
specific, and may have fewer side effects [2-7]. One example is the pleckstrin homology (PH) 
domain-dependent inhibitors of the phosphoinositide 3 kinase (PI3K)-Akt pathway, which 
exhibit selectivity and potency for individual serine/threonine kinase Akt isozymes [8]. Unlike 
the phosphatidylinositol (PI) analogs which inhibit Akt, but may also bind other PH domain 
containing proteins, the allosteric inhibitors of the individual Akt isozymes, such as MK-2206, 
appear selective for, and inhibit the activity of only Akt. In addition, because allosteric drugs do 
not block the active site and thus are not competitive with the natural substrate (ATP in this 
example), they do not act as an on/off switch for a receptor, and thus allow modulation of the 
levels of activity. Modulation can be beneficial. For example, small-molecule allosteric 
modulators of phosphodiesterase 4 (PDE4), the primary cAMP-hydrolyzing enzyme in cells, that 
do not completely inhibit enzymatic activity (Imax ~ 80-90%) have reduced potential to cause 
emesis, a dose-limiting side effect of existing active site PDE4 inhibitors, while maintaining 
biological activity. Such modulators of cAMP signaling can help central nervous system 
therapeutics where penetration to the brain is desired [9]. These advantages are reflected in the 
increasing number of allosteric drugs, from the age-old valium and the benzodiazepines to the 
more recent development of maraviroc (Selzentry) and cinacalcet (Sensipar), for AIDS and 
hyperparathyroidism, respectively [2-7]. Increasing numbers of pipelines are dedicated 
exclusively to the development of allosteric drugs. Recent examples of allosteric drugs include 
RDEA119/BAY 869766 as an allosteric mitogen-activated protein/extracellular signal-regulated 
kinase (MEK) inhibitor [10], pyrvinum, a potent allosteric inhibitor of Wnt signaling [11], 
efavirenz, an allosteric reverse transcriptase inhibitor [12] and SCF-I2, an allosteric inhibitor of 
(yeast) F-box protein Cdc4 [13].  
 
To understand how an allosteric drug works, we need to consider proteins as ensembles of states, 
where each state has a certain population. A ‘state’ is a conformation, and the ‘population’ of the 
state is the concentration that it has in solution. The allosteric effect is the change in the 
populations (called ‘population shift’) of the states upon perturbations (e.g. ligand or drug 
binding, mutations) [14-17]. The conformation in which the active site is ‘closed’ is the most 
stable; consequently, it has the highest population in solution, and the protein shows high activity 
in the cell. The inactive conformation to which the allosteric drug binds has an ‘open’ active site. 
This conformation is less stable, and thus has lower population. However, upon binding of the 
drug to the allosteric site, the inactive conformation is stabilized, thus its population increases. 
This change in the relative distributions of the conformations in solution which takes place 
following binding is a ‘population shift’. Figure 1 illustrates a schematic energy landscape 
showing a population shift between conformations upon allosteric drug binding, in this case for 
rapamycin/FKBP12 binding to the mTOR, and its consequences. Despite the clear advantages of 
allosteric drugs, allosteric designs do not always work: inhibitors can allosterically mimic a 
substrate, as in the case of a CD4 mimetic, which was designed to inhibit CD4 binding to gp120 
to prevent gp120 interaction with CCR5 cell surface receptors and HIV-1 entry, but led to the 
opposite effect. Subsequent successful designs interrupted both CD4 and CCR5 interactions and 
achieved this goal [18]. Allosteric drugs also induced activation rather than repression in the 
phosphorylation of PKC and Akt [19-20]. Other problems can also surface [21]. In particular, the 
3 
 
problem of the cell utilizing parallel pathways [22-23] is still a major hurdle [24]. These 
challenges emphasize the urgent need for additional novel strategies. 
 
In the last decade, the analysis of the topology and dynamics of cellular networks (e.g., protein-
protein interaction networks, signaling networks, gene transcription networks, metabolic 
networks) became a powerful tool to describe cellular functions in health and disease [17, 25-
37]. Networks were increasingly used to aid the discovery of novel drug binding sites and drug 
targets [38-40]. However, to date, the two levels of description have been treated as largely 
distinct approaches.  
 
Broadening the concept of allosteric drugs to allo-network drugs 
Here, we propose that combining the chemical description of proteins as conformational 
ensembles with the system-level information related to cellular networks make it possible to 
broaden our view of allosteric drug discovery to the level of the network of the whole cell [41]. 
In the cell, all proteins are interconnected. Recent observations of network-wide propagation of 
allosteric effects in disease provide striking examples of network interconnectivity [42]:  
Alzheimer and prion diseases are neurodegenerative disorders, which are characterized by the 
abnormal processing of amyloid-β (Aβ) peptide and prion protein (PrPC), respectively. PrPc can 
either bind to Aβ oligomers or inhibit β-secretase 1 (BACE1) cleavage, and these events can lead 
to Aβ toxicity, long term memory potentiation and cell death. At the same time, the expression of 
PrPC itself appears to be controlled by the amyloid intracellular domain (AICD), which is 
obtained by cleavage of γ-secretase. PrPc transcription is regulated by p53 concentration, with 
p53 itself also under tight network control.  
 
Here we argue that combining the chemical view with such network-level data may pave the way 
to novel generation of allosteric drugs which harness allostery at the cellular level. We name 
such drugs ‘allo-network drugs’. Figure 2 illustrates a comparison of orthosteric, allosteric and 
allo-network drug action. Both the ‘classical’ allosteric drug (Figure 2B) and our proposed ‘allo-
network drug’ (Figure 2C) are based on the principles of allostery and population shift (Figure 
1). Further, both will have systems level effects and unbiased cell-based screening assays would 
pick up on such compounds. The difference is that the classical allosteric drugs are designed to 
directly target a specific (misfunctional) protein, as in the case of the GPCRs. By contrast, here 
we consider other proteins of the cellular network as final targets. Allo-network drugs integrate 
the chemical view of conformational ensembles with the network view of the cell. Such 
integration can be powerful because it allows a priori targeting of other proteins in the pathway, 
and in this way expands the scope of drug discovery targets. Allo-network drug targets may 
provide a large number of potential novel targets with high selectivity and fewer side effects. 
Thus the broadened new “allo-network drug” concept combines principles of allostery and 
systems level cellular network information. Within this broad description of allo-network drugs, 
current allosteric drugs are a special case.  
 
Because allostery is an ensemble phenomenon [16], allosteric propagation can be described by a 
progressive change in the occupancy of states, that is, by the ‘population shift’ [16] (Figure 1). 
To understand how population shift takes place, consider the local perturbation that binding of a 
ligand creates: atoms which were in contact with the solvent or with neighboring atoms in the 
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same molecule now interact with ligand atoms. To retain a favorable local atomic environment, a 
reorganization of the binding site takes place. This creates strain energy, and atoms around are 
also forced to change their contacts. In this way, the strain energy spreads and propagates in the 
structure through the dynamic fluctuations in atomic contacts leading to conformational and 
dynamic changes. Because allostery is the result of any structural perturbation, this will be the 
outcome of any binding, including orthosteric inhibition (Figure 2A). Allostery is a fundamental 
concept related to statistical thermodynamics [14-17, 43]. It takes place because proteins exist in 
ensembles of states around their native conformations, and the barriers that separate these are 
low (illustrated in Figure 1). Perturbation can change the relative populations of the states, and 
the time scales of the change relate to the barrier heights separating the energy minima of the 
states on the energy landscape. The perturbation energy (thus, conformational change) dissipates 
from the binding site through multiple pathways similar to waves generated by a stone thrown 
into the water. Further, binding to one protein leads to conformational and dynamic changes in 
adjacent proteins [17] across a pathway [44]. Packing in protein structures is not homogeneous; 
and consequently the propagation of the perturbation is not isosteric. Because cellular pathways 
consist of a series of events, allostery can explain how signals can propagate in the cell [44]. 
Thus, allosteric effects can be considered either at the level of the protein; or of the cell, where 
propagation can take place via large (in the case of some processes such as transcription 
initiation even gigantic) cellular assemblies over large (~hundreds or even thousands of 
Angstroms) distances (Figure 3). 
 
Examples of allo-network effects and drugs harnessing the principles of nature 
The fast emergence of cellular resistance to conventional and allosteric drug treatments 
necessitates expansion of the repertoire of drug targets and their combinations. Specific allosteric 
shape-shifting [4-5] at the functional site can be induced by binding far away. As an example, 
transcription factors (TFs) transfer signals from specific DNA regulatory elements (REs) via the 
gigantic Mediator complex [45] to initiate gene-specific transcription hundreds of Angstroms 
away (Figure 3A). For the glucocorticoid receptor (GR), a difference of one base pair in an RE 
sequence [46] or an amino acid mutation affects transcription initiation across such distances and 
leads to a functional change. Similarly, mutations in the p53 activation domain also led to such a 
distant specific effect [47]. By contrast, a mutation in Mediator, which often bridges between 
RE-bound TFs and the RNA polymerase II (Pol II) machinery and mediates transcription 
initiation, will affect transcription of many genes (Figures 3 A,B). In Figure 3A, a change in an 
RE, or mutational effects in the TF binding sites, may propagate via Mediator modules to Pol II 
and affect transcription initiation [46-47]. Perturbations caused by drug binding may also 
propagate similar to those of mutations or RE sequence changes, and may specifically interfere 
with signaling across such pathways. This may take place by either orthosteric or allosteric drugs 
(represented by D11 and D12, respectively, in Figure 3B). In both cases, the interaction between 
the protein and its neighbor along the pathway (TF1 and the Middle module of Mediator, in 
Figure 3B) may be affected, which may hinder the functional outcome (transcription activation 
in this case). However, these drugs do not affect transcription initiation by TF2 or TF3. By 
contrast, a drug that binds Pol II (Dp in Figure 3B) will inhibit transcription of all pathways 
going through Mediator.  
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This example illustrates how networks and allostery, which have been combined by evolution for 
cellular function [48], can be copied by allo-network drugs in design. Allo-network drugs can 
make use of the specifically wired cellular functional paths and the specific interactions of their 
perturbation channels. We argue that allo-network drugs whose effects inhibit (or enhance) 
specific interactions along a pathway would harness evolution; as such, they could achieve 
specific and limited systems changes, which could be advantageous for drug regimes.  
 
Protein disorder and modular organization help allo-network drug action  
Because allosteric effects involve release of strain energy through fluctuations and changes in 
van der Waals contacts and hydrogen bonds [49], propagation will be more efficient in a tightly 
packed environment with high atomic density. A mechanism ensuring tight packing at protein 
interfaces is the evolution of disordered proteins. Disordered proteins display a two-state 
behavior: stay unfolded in their unbound state, and become folded when another protein (or 
ligand) is bound. Their protein-protein interfaces can resemble the compact hydrophobic cores of 
single-chain proteins. By using disordered proteins, evolution engineered tight interfaces which 
can allow rapid long-range transfer of regulatory cues. The level of protein disorder has 
increased in human cells [50]. Disordered protein regions and the coupled large assemblies, 
along with the spatial functional modularity in the cell, amplify the allosteric relay [44]. The 
complexity of regulation has increased in higher organisms through binding of additional factors, 
as for example shown in the transcriptional Mediator assembly [45, 51]. There is a much larger 
number of signaling cross-talks in human cells than in Drosophila or C. elegans [52]. A recent 
study showed that denser networks are easier to regulate [53]. Thus, allo-network drug-like 
action occurs most where it is needed most: in human cells.  
 
Allo-network drugs and multi-drug targets as specific effectors of diseased cells 
Targeted therapies are considered to be less toxic and better tolerated than general 
chemotherapies because they target specific proteins and pathways. Promising allo-network 
drugs should interfere with disease-specific pathways. One example is the modulation of the 
PI3K pathway, a signaling network which is crucial to the growth and survival of many epithelial 
cancers: when a single targeted therapy was effective, the targeted proteins and pathways were 
observed to be master regulators of several pro-growth and pro-survival signaling pathways such 
as the PI3K/Akt, Raf/ERK, and Jak/Stat, which were all up-regulated in tumor cells [23]. An 
additional example relates to the HER2/EGFR and the c-Jun amino-terminal kinase (JNK)/c-Jun 
signaling pathways: the lapatinib inhibitor used in combination with anticancer agent 
capecitabine in targeted therapy against metastatic breast cancer, was found to also improve the 
proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and two 
TRAIL receptor agonists in colorectal cancer [54]. Nonetheless, targeted therapies can also have 
side effects, such as cardiac toxicity in anti-HER2 therapy in combination with anthracyclines 
and inhibitors of angiogenesis. These again emphasize that the cellular network is inter-
connected.   
 
Combination therapies and multi-target drugs can provide a number of examples of allo-network 
drugs, because they combine multiple effects, often at places distant from the malfunctioning 
protein in the cellular network [25, 55]. As an example of allo-network multi-target action we 
describe the combination of MEK and B-RAF inhibition, which appears to be an efficient 
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method to overcome tumor resistance against MEK inhibition therapy. Mutations typically arise 
to inhibitors targeting the active site. This can also take place against allosteric inhibitors, as was 
shown recently in COT, a serine/threonine kinase member of the MAPK family. Enhanced 
expression of COT activates the MAPK and the JNK pathways as well as stimulates the nuclear 
factor of activated T cells (NF-AT) and nuclear factor kappa B (NF-κB)-dependent transcription 
[56]. M307, a short-term culture derived from a B-RAF(V600E) tumor, developed resistance to 
the allosteric MEK inhibitor AZD6244 [57]. To uncover the possible mechanisms, clones 
resistant to the allosteric MEK inhibitor AZD6244 were also generated from two B-
RAF(V600E) mutant colorectal cancer cell lines that were also highly sensitive to B-RAF 
inhibition [24]. The inhibition potency of the allosteric MEK inhibitor AZD6244 was restored by 
a B-RAF inhibitor. The combined efficiency of MEK and B-RAF inhibition, which overcame the 
resistance to MEK inhibitors, emphasizes the importance of knowledge at the cellular network 
level. The B-RAF inhibitor here may be regarded as a prototype of allo-network drugs acting at 
an adjacent protein, with MEK providing an efficient strategy to overcome the initial resistance. 
The serine/threonine kinase mammalian target of rapamycin (mTOR) provides a second example 
which also shows possible roles of compounds and signaling molecules (Figure 4). mTOR 
controls key cellular processes such as cell survival, growth and proliferation, and is frequently 
hyperactivated in a number of human malignancies [58-59]. mTOR is present in two distinct 
complexes, mTORC1 and mTORC2. Rapamycin/FKBP12 binds to mTOR and allosterically 
inhibits mTORC1 signaling but not to mTORC2, thus efficiently inhibiting some functions of 
mTOR but not all. However, mTORC2 is sensitive to prolonged rapamycin treatment which 
impedes mTORC2 assembly. Binding of rapamycin/FKBP12 to mTOR interferes with the ability 
of mSin1 and rictor to form mTORC2 and thus downstream signaling. Figure 4 illustrates how 
this example can provide insight into allo-network drugs. Increased activity of AKT and over-
expression of S6K correlate with rapamycin activity.  
 
Possible steps and methods to identify allo-network drug targets 
Discovery of allo-network drug targets and sites may work as evolution; that is, via a trial-and-
error strategy. Nonetheless, we argue that systems-level knowledge has reached a point which 
could allow higher efficiency of drug design. Below, we provide possible steps. 
1. Mapping the network: The rapid increase in experimental structural and functional data 
combined with large scale modeling tools facilitate prediction of which proteins interact and 
how they interact [60]. The integration of the data and predictions helps the construction of 
the structural cellular pathways and of large, multi-molecular assemblies.  
2. Analysis of the network to identify pathways: experimentally, this can involve for example, 
pathway profiling and cell-based pathway screening to characterize pathway selectivity for 
candidate inhibitors and specific signaling events, e.g., protein dislocation, degradation, 
secretion and expression; investigation of the interplay between signaling pathways; high-
throughput RNAi screening to dissect cellular pathways and characterize gene functions; and 
using small molecules as probes of cellular pathways and networks, as for example in the 
Rho pathway in cytokinesis. Small molecules can be used not only as therapeutics to treat 
disease, but also as tools to probe complex biological processes [61]. Theoretical network 
tools can also help. For example, a bottom-up approach [38, 55] to simulate the 
superimposed action of allo-network drugs with disease-specific intracellular pathways; or 
top-down reverse engineering methods [62] to discriminate between ‘high-’ and ‘low-
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intensity’ pathways. In the case of directed networks, such as signaling or metabolic 
networks, we may construct tree-like hierarchies [63] to gauge the importance of various 
nodes, or find driver nodes controlling the network [53]. 
3. Identification of allosteric binding sites: experimentally, assays have been developed for 
detecting non-competitive modulators of protein-protein interactions targeting protein kinase 
A (PKA) [64]. A general computational strategy for identification of allosteric sites (e.g. D12 
in Figure 3B) may involve finding correlated motions between binding sites through 
examination of covariance matrix maps. Comparison of such maps can reveal which residue–
residue correlated motions change upon ligand binding and thus can suggest new allosteric 
sites [65]. The allosteric SCF-I2 inhibitor of the SCF(Cdc4) ubiquitin ligase [13] provides 
experimental validation of an initial phase of this strategy.  
 
Here, rather than tackling directly the flat protein-protein interfaces, we employ allostery through 
a pathway. Overall, detailed structural and functional knowledge and understanding of the 
pathways, the attributes and the information flow in the cellular network can offer guidelines to 
help circumvent the long trial-and-error process which was followed by evolution. 
 
Concluding remarks 
To allow cells to rapidly respond to changing conditions, evolution utilized compact interactions 
via conformational protein disorder, modular functional organization, and large multimolecular 
assemblies; all can facilitate dynamic signaling events over large distances. The allo-network 
drug concept we introduced here makes use of this functional attribute: it proposes to target 
malfunctioning proteins not only directly, but also via other proteins. Nature has shown that 
signaling can create a limited, specific, far away network functional change. We suggest that 
allosteric drugs can harness the same principles. Extending the repertoire of allosteric drugs by 
aiming at proteins other than the direct target could provide additional drug target candidates and 
help to reduce side effects. If those proteins share the target function, are in the same module, 
and are tightly bound (which allow efficient signal propagation), such a proposition could 
constitute an alternative drug strategy. We predict that methods utilizing structural and systems 
level knowledge to identify allo-network drug targets will significantly increase in the near 
future, and hope that these will lead to a next generation of medications with greater selectivity 
and effectiveness. Among these, key steps include (i) obtaining structures of proteins and their 
complexes and mapping them into low resolution EM density maps; (ii) relating the obtained 
structural maps to function to figure out key check points and allosteric propagation pathways; 
(iii) figuring out forward and backward loops; (iv) putting the structural pathways together to 
obtain a global picture of the cellular network in atomic resolution. These can reveal what goes 
wrong in disease, and possible toxic effects. Illustrating this by the mTOR pathway example, 
only if we have the structures of the mTORC1 and mTORC2 complexes and their interactions 
with subsequent components of the mTOR pathway, will we be able to understand its functional 
complexity, and why rapamycin/FKBP12 allosterically inhibits mTORC1 signaling but not 
mTORC2, while it is able to inhibit the assembly of the mTORC2 assembly over time (Figure 4) 
[58-59, 66]. Further, (v) Allosteric regulation of biological macromolecules is affected by both 
conformational and dynamic properties of the proteins and their complexes [67]. Trapping a 
protein in its inactive state [68] is expected to be a powerful strategy in allo-network drug 
discovery. This is because binding to a complementary conformation is faster. If the stability of 
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that conformation is high, it will exist in solution in high population, which largely circumvents 
the need for a population shift and climbing over the barriers of the energy landscape (Figure 1). 
The challenge is to predict the conformational dynamics and the distributions of the states in 
solution, and even more so, the re-distribution following an allosteric event. To help this 
significant progress is being made using combination of spectroscopic techniques, particularly 
nuclear magnetic resonance (NMR), crystallography and molecular dynamics simulations [69]. 
Finally (vi), combining structural data with dynamics on the systems level under different 
conditions, such as mutational events [41], which can provide clues into alternative pathways in 
disease. This should also allow prediction of potentially harmful drug consequences. Despite the 
immense challenges, because such therapeutic development harnesses those same mechanisms 
which are used by nature, this should be possible. 
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Figure 1. A schematic, simplified energy landscape which illustrates a population shift between 
conformations upon allosteric drug binding. The experimentally purified mTORC1 (mammalian target of 
rapamycin complex 1, for which there is a cryo-EM structure) system is used as an example. The figure 
reflects the changes in the activities of the two target proteins (S6Ks and 4E-BPs) after the 
FKBP12/rapamycin binds. In the drawing, the three free energy wells represent three conformational 
states of mTORC1. The conformation is labeled at the top of the well, and the activity is indicated at the 
bottom. Purified mTORC1 is shown by cryo-EM to have a preferred dimer conformation [66]. Therefore, 
a higher population time of the dimer (which is apparently the active form) in a lower free energy state is 
expected as depicted on the left. Upon FKBP12/rapamycin binding, S6Ks activity is inhibited without an 
appreciable delay; on the other hand, a time delay is observed for the 4E-BPs inhibition. Thus, in the 
landscape drawing (on the right), there is a low barrier between the two dimer conformations, “S6Ks 
inhibited” and “4E-BPs active”, and a high barrier separates the dimer state from the monomer state. 
While in the purified system mTORC2 assembly is resistant to FKBP12/ramapycin and becomes sensitive 
only after a prolonged delay, in the cell the delay is not as long, probably because of involvement of 
additional factors. Figure 4 provides additional details.    
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Figure 2. Comparison of orthosteric, allosteric and allo-network drugs. Here, in all cases the effect of the 
drug on the target site is via an allosteric propagation. Intra-protein propagation of drug-induced 
conformational changes is represented by dark green arrows. Conformational changes propagating 
through multiple proteins are marked with light green arrows. Drug binding sites are depicted by green 
circles; target sites are highlighted by red asterisks. (A) Orthosteric drugs. Here the inhibition (or 
activation, illustrated by light red ellipsoids at the bottom row) is via an allosteric effect which is elicited 
by active site (orthosteric) binding and propagates to a target site (dark green arrow). Because protein 
families often share similar binding pockets, orthosteric drugs can bind to multiple proteins (named here 
‘isoform 1’ and ‘isoform 2’), which can lead to side effects. (B) Allosteric drugs. Drug binding is in an 
allosteric site. Allosteric drugs are more specific than orthosteric drugs, because they usually do not bind 
to isoforms of the target. (C) Allo-network drugs. Here, drug binding is at an allosteric site; however, the 
target site is on a different protein in the cellular network. The pathway of allo-network drug-induced 
conformational changes (marked by light green arrows) may be highly specific and (or) specifically 
enhance (or inhibit) an intracellular pathway of propagating conformational changes (marked by orange 
arrows) at the target site. In promising allo-network drugs these intracellular pathways are disease-
specific.  
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Figure 3. An example of specific, long-range allosteric propagation (on the order of hundreds or 
thousands of Angstroms) taken from nature. Here we propose that an allo-network drug can harness such 
regulatory pathways. The example involves gene-specific transcription initiation. (A) A schematic 
diagram illustrating transcription signal transduction from the DNA response element (RE), through 
transcription factor (TF) and the Mediator complex to the RNA polymerase II (Pol II) transcription 
machinery. For clarity, only the TATA-binding protein (TBP), Pol II and nucleosome-free DNA promoter 
are included in the drawing of the Pol II transcription machinery, instead of all the units involved in the 
pre-initiation complex (PIC). Between the RE and the Pol II transcription machinery, the DNA, which is 
covered with nucleosomes, is looped-out with variable lengths. While the TF is drawn with an arbitrary 
shape, the projected 2-D shape of Mediator and Pol II and their associations are based on cryo-EM 
structures. Mediator has three modules: Tail, Middle and Head. The long, multiunit-spanning 
transcription signal in the form of allosteric propagation starts from the RE via the TF, to the Tail, 
Middle, and Head modules of Mediator and finally down to Pol II. Three possible allo-network regulation 
sites are highlighted in pink circles.  (B) A simplified transcriptional network.  Only three transcription 
factors (TFs) and seven response elements (REs) are drawn here to illustrate transcriptional regulation in 
terms of allosteric propagations via REs, TFs and Mediator, down to RNA polymerase II (Pol II). Each 
TF has many REs and different TFs may bind different Mediator module (here Tail or Head), and has 
different propagation pathway. Each circle, a node of the network, represents either a segment of DNA 
(RE) or a group of proteins. Two arcs connected by a line represent either a protein-DNA or protein-
protein interaction. An arc with many connected lines reflects the same interface of the node involved in 
interaction with different partners. The three pink arrows indicate three individual propagation pathways 
initiating at the interactions between REs and TFs and ending at the interface between Mediator Head and 
Pol II as depicted in Figure 3A. In terms of the local network, the drug D11 that binds directly at the TF1 
DNA binding site is an orthosteric drug which prevents TF1 from binding to RE11, RE12, RE13, RE14 and 
RE15. On the other hand, the scenario where drug D12 binds to TF1 far from the DNA binding site where 
the resulting allosteric effect only prevents TF1 binding to RE12, labels D12 as an allosteric drug whose 
function is to turn off the TF1-RE12 regulation. However, in terms of the global network, both drugs are 
allo-network drugs which alter all or some functions of TF1 but do not perturb the function of TF2 and TF3 
through the same Mediator-Pol II transcription regulation pathway, as compared to the drug Dp that binds 
Pol II at the interface with Mediator head thus shutting off all three TF regulatory functions. 
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Figure 4. A schematic network of the mTORC1 and mTORC2 regulatory interactions. The network in 
the figure illustrates how FKBP12/rapamycin inhibits the phosphorylation of two target proteins, S6Ks 
(S6 kinase) and 4E-BPs (eukaryotic translation initiation factor 4E (eIF4E)-binding proteins), which are 
involved in the regulation of translation initiation. As in Figure 3B, each circle represents a domain, a 
protein or a group of proteins. Two arcs connected by a line represent protein-protein interaction. Circles 
in blue represent the assemblies of mTORC1. Rictor (a component of mTORC2) is in pale yellow, the 
drugs are in pink color, and the substrates of mTOR are colored in orange. The network representation is 
mainly based on the cryo-EM dimer structure of mTOR complex 1 (mTORC1) [66]. Upon binding of 
FKBP12/rapamycin to the FRB domain of mTOR, two possible allosteric propagation pathways 
(indicated by the pink arrows) can initiate at the interface between FKBP12/rapamycin and FRB: in the 
first, the propagation ends at the interaction of the mTOR C-terminal and the protein raptor in mTORC1 
(or rictor, an exclusive partner of mTOR in the mTORC2 assembly; raptor and rictor appear to occupy the 
same surface on mTOR); in the second, the propagation ends at the interaction of mTOR C-terminal and 
the S6Ks substrate. It is not clear (as indicated by two question marks) whether the inhibition of S6Ks 
phosphorylation is because of the weakened recruitment of the second allosteric propagation or because 
of a steric exclusion as shown by the overlap between S6Ks and FKBP12/rapamycin complex. In 
mTORC1, the first allosteric propagation disrupts the association between raptor and mTOR C-terminal 
domain, which then prevents raptor from recruiting the substrate 4E-BPs in its (active) dimer-bound form, 
as indicated by the dashed pink arrow. Because raptor mediates the mTOR dimer interaction, now mTOR 
is a monomer. If we include the role of raptor in 4E-BPs phosphorylation, rapamycin is an allo-network 
drug. For clarity, the interactions between the substrates and the catalytic site of mTOR, at which the 
Torin1 drug binds, are not drawn.  
